Sirtuin 3/SIRT3 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NB600-808
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Peptide ELISA, Western Blot
Cited:
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Peptide with sequence C-QRETGKLDGPDK, from the C Terminus of the protein sequence according to NP_036371.1, NP_001017524.1.
Specificity
This antibody is expected to recognize both reported isoforms (NP_036371.1 and NP_001017524.1).
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for Sirtuin 3/SIRT3 Antibody
Western Blot: Sirtuin 3/SIRT3 Antibody [NB600-808]
Western Blot: Sirtuin 3/SIRT3 Antibody [NB600-808] - Staining of human liver lysate (35 ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.Applications for Sirtuin 3/SIRT3 Antibody
Application
Recommended Usage
Peptide ELISA
Detection limit 1:128000
Western Blot
0.1 - 0.3 ug/ml
Application Notes
WB: Approx 28 kDa band observed in human liver lysates (calculated MW of 28.6 kDa according to NP_001017524.1).
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: Sirtuin 3/SIRT3
Long Name
Silent Mating Type Information Regulation 3 Homolog
Alternate Names
SIR2-like protein 3, SIR2L3, SIRT3
Entrez Gene IDs
23410 (Human)
Gene Symbol
SIRT3
UniProt
Additional Sirtuin 3/SIRT3 Products
Product Documents for Sirtuin 3/SIRT3 Antibody
Product Specific Notices for Sirtuin 3/SIRT3 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...